Arla Foods Ingredients is demonstrating how its new protein ingredient Lacprodan® BLG-100 (purified beta-lactoglobulin) can deliver benefits to people suffering from Chronic Kidney Disease (CKD).
CKD is a progressive decline in kidney function which may eventually lead to End Stage Renal Disease (ESRD). It affects more than 850 million adults worldwide and accounts for one million deaths each year1, with these figures expected to rise. When renal functions deteriorate, CKD patients find it increasing difficult to cope with maintaining sufficient dietary intake of protein while avoiding excessive intake of minerals such as phosphorous, potassium, sodium and calcium.
To demonstrate how manufacturers can create products to help CKD patients, Arla Foods Ingredients is introducing two solutions using Lacprodan® BLG-100: a ready-to-drink (RTD) beverage with 7% protein, and a shot format containing 21% protein.
The RTD has been nutritionally designed with 7% protein, 10% fat and 20% carbohydrates to support people with Stage 1 to 5 Chronic Kidney Disease who are not in dialysis. The use of Lacprodan® BLG-100 means the low viscosity beverage has a minimal phosphorous content compared with the majority of other commercially available alternatives.
The second option is a high-protein shot solution, which has been specifically formulated for the dietary management of people living with CKD who are in dialysis, and who have fluid intake limitations or high protein requirements. This application is ideal for supporting the control of phosphorous levels in the body while also getting high-quality protein into the diet.
Mads Dyrvig, Head of Health and Performance Sales Development, said: “While minerals are essential to life, too much is a serious issue if your body has a reduced capacity to excrete it. The nutritional challenge for someone with CKD is that many of the foods we eat, such as meat and dairy, are rich in phosphorous. People diagnosed with CKD are advised to reduce dietary protein intake significantly. The dilemma is that for a CKD patient, phosphorus accumulation in the body increases the risk of heart attacks and strokes and may lead to cardiovascular disease, whereas the alternative is reducing protein intake and gradually losing significant muscle mass (muscle atrophy). Both conditions increase mortality risk while muscle atrophy also decreases the quality of life for patients.
He continued: “The majority of commercially available Oral Nutritional Supplements (ONS) contain a relatively high mineral content, including phosphorous. Arla Foods Ingredients can close this gap in the market with Lacprodan® BLG-100 , which is low in minerals, has an excellent nutritional profile and offers great benefits in terms of muscle preservation.”
“Our 100% pure BLG ingredient is rich in essential amino acids and leucine, so it contains high quality proteins, which meet the nutritional needs of CKD and ESRD patients. It is also extremely low in phosphorous and hence is a great solution for medical nutrition products because it enables the supplementation of protein without compromising requirements for a low mineral intake.”
Earlier this year Arla Foods Ingredients’ Novel food application for Lacprodan® BLG-100 received a positive EFSA opinion, confirming it is safe and suitable for use in food products in the EU. Furthermore, Lacprodan® BLG-100 recently received the American Dairy Products Institute (ADPI) 2022 Breakthrough Award for Dairy Ingredient Innovation.
1 Jager KJ et al. A single number for advocacy and communication – worldwide more than 850 million individuals have kidney disease. Kidney Int 96, pg. 1048-1050, 2019).